BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 27, 2019
Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic  Orexo AB (SSE:ORX) licensed exclusive U.S. rights from GAIA AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo...
BC Extra | Aug 21, 2019
Company News

Orexo, GAIA to develop digital therapeutic for opioid use disorder

Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD). For its first digital...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
BC Week In Review | Dec 21, 2018
Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

Orexo AB (SSE:ORX) will regain global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo, which holds U.S. rights to the drug, said the news follows a portfolio reorganization...
BC Extra | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
BC Extra | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
Items per page:
1 - 10 of 273
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 27, 2019
Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic  Orexo AB (SSE:ORX) licensed exclusive U.S. rights from GAIA AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo...
BC Extra | Aug 21, 2019
Company News

Orexo, GAIA to develop digital therapeutic for opioid use disorder

Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD). For its first digital...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
BC Week In Review | Dec 21, 2018
Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

Orexo AB (SSE:ORX) will regain global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo, which holds U.S. rights to the drug, said the news follows a portfolio reorganization...
BC Extra | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
BC Extra | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
Items per page:
1 - 10 of 273